Oncolytic viral therapy for cervical and ovarian cancer cells by sindbis virus AR339 strain

Clinical Cancer Research

Volumn 11, Issue 12, 2005, Pages 4553-4560

  Unno, Youichi ^a   Shino, Yuji ^a   Kondo, Fukuo ^b   Igarashi, Natsuhiko ^a   Wang, Gang ^a   Shimura, Ryuhi ^a   Yamaguchi, Taketo ^a   Asano, Takehide ^c   Saisho, Hiromitsu ^a   Sekiya, Souei ^a   Shirasawa, Hiroshi ^a  

^a CHIBA UNIVERSITY   (Japan)

^b Funabashi Central Hospital   (Japan)

^c CHIBA CANCER CENTER   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; GREEN FLUORESCENT PROTEIN; ONCOLYTIC VIRUS;

ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CELL DEATH; CELL VIABILITY; CONTROLLED STUDY; DRUG TARGETING; FEASIBILITY STUDY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; INOCULATION; MOUSE; NONHUMAN; NUDE MOUSE; OVARY CARCINOMA; PRIORITY JOURNAL; PROTEIN SYNTHESIS; SINDBIS VIRUS; SINDBIS VIRUS AR339 STRAIN; TREATMENT OUTCOME; UTERINE CERVIX CARCINOMA; VIRAL GENE THERAPY; VIROGENESIS; VIRUS STRAIN;

ANIMALS; APOPTOSIS; BLOTTING, WESTERN; CELL LINE, TUMOR; FEMALE; GREEN FLUORESCENT PROTEINS; HELA CELLS; HUMANS; MICE; MICE, INBRED BALB C; MICE, NUDE; MICROSCOPY, FLUORESCENCE; ORTHOREOVIRUS; OVARIAN NEOPLASMS; SINDBIS VIRUS; UTERINE CERVICAL NEOPLASMS; VIRAL PROTEINS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 20444461981     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-04-2610     Document Type: Article

References (26)

1. Kirn D, Martuza RL, Zwiebel J. Replication-selective virotherapy for cancer: Biological principles, risk management and future directions. Nat Med 2001;7:781-7.
2. Biederer C, Ries S, Brandts CH, McCormick F. Replication-selective viruses for cancer therapy. J Mol Med 2002;80:163-75.
3. Ring CJ. Cytolytic viruses as potential anti-cancer agents. J Gen Virol 2002;83:491-502.
4. Griffin DE. Alphaviruses. In: Knipe DM, Howley PM, editors. Fields virology, ed. 4. Philadelphia: Lippincott Williams and Wilkins; 2001. p. 917-62.
5. Tseng JC, Levin B, Hirano T, Yee H, Pampeno C, Meruelo D. In vivo antitumor activity of Sindbis viral vectors. J Natl Cancer Inst 2002;94:1790-802.
6. Jan JT, Griffin DE. Induction of apoptosis by Sindbis virus occurs at cell entry and does not require virus replication. J Virol 1999;73:10296-302.
7. Moriishi K, Koura M, Matsuura Y. Induction of Bad-mediated apoptosis by Sindbis virus infection: involvement of pro-survival members of the Bcl-2 family. Virology 2002;292:258-71.
8. Wang KS, Kuhn RJ, Strauss EG, Ou S, Strauss JH. High-affinity laminin receptor is a receptor for Sindbis virus in mammalian cells. J Virol 1992;66:4992-5001.
9. van den Brule FA, Castranovo V, Menard S, et al. Expression of the 67 kD laminin receptor in human ovarian carcinomas as defined by a monoclonal antibody, MLuCS. Eur J Cancer 1996;32:1598-602.
10. al-Saleh W, Delvenne P, van den Brule FA, Menard S, Boniver J, Castronovo V. Expression of the 67 KD laminin receptor in human cervical preneoplastic and neoplastic squamous epithelial lesions: an immunohistochemical study. J Pathol 1997;181:287-93.
11. Yamanaka R. Alphavirus vectors for cancer gene therapy. Int J Oncol 2004;24:919-23.
12. Hirasawa K, Nishikawa SG, Norman KL, Alain T, Kossakowska A, Lee PW. Oncolytic reovirus against ovarian and colon cancer. Cancer Res 2002;62:1696-701.
13. Sekiya S, Tanaka N, Takamizawa H. Production of various marker substances in human ovarian cancer cell lines of epithelial origin. Arch Gynecol Obstet 1990; 248:103-10.
14. Kawamata Y, Mitsuhashi A, Unno Y, et al. HPV 16-E6-mediated degradation of intrinsic p53 is compensated by up-regulation of p53 gene expression in normal cervical keratinocytes. Int J Oncol 2002; 21:561-7.
15. Thomas JM, Klimstra WB, Ryman KD, Heidner HW. Sindbis virus vectors designed to express a foreign protein as a cleavable component of the viral structural polyprotein. J Virol 2003;77:5598-606.
16. Nozawa CM, Apostolov K. Association of the cytopathic effect of sindbis virus with increased fatty acid saturation. J Gen Virol 1982;59:219-22.
17. Tatem J, Stollar V. Effect of Sindbis virus infection on induction of heat shock proteins in Aedes albopictus cells. J Virol 1989;63:992-6.
18. Antalis TM, La Linn M, Donnan K, et al. The serine proteinase inhibitor (serpin) plasminogen activation inhibitor type 2 protects against viral cytopathic effects by constitutive interferon α/β priming. J Exp Med 1998;187:1799-811.
19. Higashikawa F, Chang L. Kinetic analyses of stability of simple and complex retroviral vectors. Virology 2001;280:124-31.
20. DePolo NJ, Harkleroad CE, Bodner M, et al. The resistance of retroviral vectors produced from human cells to serum inactivation in vivo and in vitro is primate species dependent. J Virol 1999;73:6708-14.
21. Alemany R, Suzuki K, Curiel DT. Blood clearance rates of adenovirus type 5 in mice. J Gen Virol 2000; 81:2605-9.
22. Sung RS, Qin L, Bromberg JS. TNFα and IFNγ induced by innate anti-adenoviral immune responses inhibit adenovirus-mediated transgene expression. Mol Ther 2001;3:757-67.
23. Klimstra WB, Ryman KD, Johnston RE. Adaptation of Sindbis virus to BHK cells selects for use of heparan sulfate as an attachment receptor. J Virol 1998;72:7357-66.
24. Byrnes AP, Griffin DE. Large-plaque mutants of Sindbis virus show reduced binding to heparan sulfate, heightened viremia, and slower clearance from the circulation. J Virol 2000;74:644-51.
25. Cook SH, Griffin DE. Luciferase imaging of a neurotropic viral infection in intact animals. J Virol 2003; 77:5333-8.
26. Tseng JC, Levin B, Hurtado A, et al. Systemic tumor targeting and killing by Sindbis viral vectors. Nat Biotechnol 2004;22:70-7.